These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 31507106)
21. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series. Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972 [TBL] [Abstract][Full Text] [Related]
23. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population. Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416 [TBL] [Abstract][Full Text] [Related]
24. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Pratt PK; David N; Weber HC; Little FF; Kourkoumpetis T; Patts GJ; Weinberg J; Farraye FA Inflamm Bowel Dis; 2018 Jan; 24(2):380-386. PubMed ID: 29361083 [TBL] [Abstract][Full Text] [Related]
25. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394 [TBL] [Abstract][Full Text] [Related]
26. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab. Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159 [TBL] [Abstract][Full Text] [Related]
28. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839 [TBL] [Abstract][Full Text] [Related]
29. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281 [TBL] [Abstract][Full Text] [Related]
30. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161 [TBL] [Abstract][Full Text] [Related]
31. Safety of infliximab in children with IBD: the experience of an academic center in WV. Northcutt M; Al-Subu A; Bella B; Elitsur Y W V Med J; 2014; 110(3):26-9. PubMed ID: 24984403 [TBL] [Abstract][Full Text] [Related]
32. Adverse reactions to infliximab and the outcome of desensitization. Mourad AA; Boktor MN; Yilmaz-Demirdag Y; Bahna SL Ann Allergy Asthma Immunol; 2015 Aug; 115(2):143-6. PubMed ID: 26093777 [TBL] [Abstract][Full Text] [Related]
33. Premedication Use Before Infliximab Administration: A Cross-sectional Analysis. Picoraro J; Winberry G; Siegel CA; El-Matary W; Moses J; Grossman A; Park KT Inflamm Bowel Dis; 2017 Jan; 23(1):174-180. PubMed ID: 28002131 [TBL] [Abstract][Full Text] [Related]
34. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689 [TBL] [Abstract][Full Text] [Related]
35. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. Radin M; Sciascia S; Roccatello D; Cuadrado MJ BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633 [TBL] [Abstract][Full Text] [Related]
36. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study. Szymanska E; Dadalski M; Sieczkowska-Golub J; Jarzebicka D; Meglicka M; Osiecki M; Wiernicka A; Lebensztejn DM; Korczowski B; Kierkus J J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300342 [TBL] [Abstract][Full Text] [Related]